Logo image of PMN.CA

ProMIS Neurosciences Inc (PMN.CA) Stock Fundamental Analysis

TSX:PMN - Toronto Stock Exchange - CA74346M4065 - Common Stock - Currency: CAD

6  -0.24 (-3.85%)

Fundamental Rating

0

PMN gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 24 industry peers in the Biotechnology industry. Both the profitability and financial health of PMN have multiple concerns. PMN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PMN had negative earnings in the past year.
PMN had a negative operating cash flow in the past year.
PMN had negative earnings in each of the past 5 years.
In the past 5 years PMN always reported negative operating cash flow.
PMN.CA Yearly Net Income VS EBIT VS OCF VS FCFPMN.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -5M -10M -15M -20M

1.2 Ratios

PMN has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PMN.CA Yearly ROA, ROE, ROICPMN.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K

1.3 Margins

PMN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PMN.CA Yearly Profit, Operating, Gross MarginsPMN.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -20K -40K -60K

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for PMN has been increased compared to 1 year ago.
There is no outstanding debt for PMN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PMN.CA Yearly Shares OutstandingPMN.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M
PMN.CA Yearly Total Debt VS Total AssetsPMN.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -17.22, we must say that PMN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -17.22, PMN is doing worse than 70.97% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -17.22
ROIC/WACCN/A
WACCN/A
PMN.CA Yearly LT Debt VS Equity VS FCFPMN.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 5M -5M -10M -15M

2.3 Liquidity

PMN has a Current Ratio of 0.51. This is a bad value and indicates that PMN is not financially healthy enough and could expect problems in meeting its short term obligations.
PMN's Current ratio of 0.51 is on the low side compared to the rest of the industry. PMN is outperformed by 70.97% of its industry peers.
A Quick Ratio of 0.51 indicates that PMN may have some problems paying its short term obligations.
PMN's Quick ratio of 0.51 is on the low side compared to the rest of the industry. PMN is outperformed by 70.97% of its industry peers.
Industry RankSector Rank
Current Ratio 0.51
Quick Ratio 0.51
PMN.CA Yearly Current Assets VS Current LiabilitesPMN.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

PMN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -203.88%.
PMN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-203.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85.38%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, PMN will show a small growth in Earnings Per Share. The EPS will grow by 5.72% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.65%
EPS Next 2Y5.66%
EPS Next 3Y-5.37%
EPS Next 5Y5.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PMN.CA Yearly Revenue VS EstimatesPMN.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2017 2018 2019 2020 2021 2028 2029 2030 50M 100M 150M 200M 250M
PMN.CA Yearly EPS VS EstimatesPMN.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PMN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PMN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PMN.CA Price Earnings VS Forward Price EarningsPMN.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PMN.CA Per share dataPMN.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3

4.3 Compensation for Growth

PMN's earnings are expected to decrease with -5.37% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.66%
EPS Next 3Y-5.37%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PMN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ProMIS Neurosciences Inc

TSX:PMN (7/21/2023, 7:00:00 PM)

6

-0.24 (-3.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.03%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap51.48M
Analysts80
Price Target26.52 (342%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.29%
EPS NY rev (3m)1.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.5
EYN/A
EPS(NY)-2.43
Fwd EYN/A
FCF(TTM)-2.54
FCFYN/A
OCF(TTM)-2.54
OCFYN/A
SpS0
BVpS-0.95
TBVpS-0.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.51
Quick Ratio 0.51
Altman-Z -17.22
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)193.61%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-203.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85.38%
EPS Next Y-11.65%
EPS Next 2Y5.66%
EPS Next 3Y-5.37%
EPS Next 5Y5.72%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-113.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.81%
EBIT Next 3Y-8.76%
EBIT Next 5Y8.97%
FCF growth 1Y-307.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-318.48%
OCF growth 3YN/A
OCF growth 5YN/A